Table 1.
Demographics and patient characteristics for suspected or confirmed COVID-19 cases (to 15 January 2021).
| All patients (n=261)a | |
|---|---|
| Median age, years (range) | 41 (18–73) |
| Aged ≥60 years, n (%) | 15 (5.7) |
| Not reported, n (%) | 51 (19.5) |
| Sex, n (%) | |
| Male | 57 (21.8) |
| Female | 182 (69.7) |
| Not reported | 22 (8.4) |
| Confirmed COVID-19, n (%) | 160 (61.3) |
| Asymptomatic, n (%) | 21 (8.0) |
| Median time to COVID-19 from most recent treatment course, days (range) | 162 (0–643); n=139 |
| Most recent course of cladribine tablets treatment before COVID-19, n (%) | |
| Year 1 | 87 (33.3) |
| Year 2 | 32 (12.3) |
| Unknown or not reported | 142 (54.4) |
| Serious COVID-19 cases (n=40) | |
| Median age, years (range) | 47 (24–73) |
| Aged ≥60 years, n (%) | 7 (17.5) |
| Not reported, n (%) | 1 (2.5) |
| Sex, n (%) | |
| Male | 9 (22.5) |
| Female | 31 (77.5) |
| Confirmed COVID-19, n (%) | 29 (72.5) |
| Median time to COVID-19 from most recent treatment course, days (range) | 162 (4–643); n=31 |
| Most recent course of cladribine tablets treatment before COVID-19, n (%) | |
| Year 1 | 19 (47.5) |
| Year 2 | 3 (7.5) |
| Unknown or not reported | 18 (45.0) |
a
An additional 11 patients had symptoms compatible with COVID-19 but were not evaluated further given negative PCR tests.